TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21585706
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + cisplatin-based chemotherapy
Study: 17028377
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg zinc daily for 4 weeks
Study: 9438895
Drug: Granisetron 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 3.0 mg
Study: 1976664
Drug: Cetirizine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine, 20 mg/day for 4 days
Study: 416195
Drug: Peripheral total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral total parenteral nutrition (TPN) consisting of casein hydrosylate, dextrose, and soybean emulsion
Study: 31558398
Drug: Intravenous thiamine
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous thiamine (600 mg on the day of surgery, and 400 mg/day on postoperative days 1, 2, and 3)
Study: 12478408
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1 g t.i.d.)
Study: 22584353
Drug: Preemptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive therapy with valganciclovir (900 mg b.i.d. for a minimum of 14 days)
Study: 22584353
Drug: Deferred therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred therapy
Study: 18030070
Drug: Usual drug
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual drug therapy
Study: 23830530
Drug: Subcutaneous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous fentanyl
Study: 1710631
Drug: Histamine hydrochloride
Normalized name: Histamine hydrochloride
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine hydrochloride (10 and 100 mg/ml)
Study: 1710631
Drug: Substance P
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance P (50 and 500 ng per injection site)
Study: 1710631
Drug: Phentolamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (20 micrograms per injection site)
Study: 1710631
Drug: Carbachol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbachol (1 microgram per injection site)
Study: 31609865
Drug: Single 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 12.5 mg naltrexone oral dose (SI group)
Study: 31609865
Drug: Escalating dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating dosage regimen starting from 50 μg up to a cumulative dose of 12.5 mg (ED group)
Study: 28444488
Drug: Prophylactic swallowing
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic swallowing exercises, completed twice daily
Study: 26837474
Drug: Selumetinib (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (75 mg twice daily) plus Docetaxel (75 mg/m2, intravenously on day 1 of every 21-day cycle)
Study: 26837474
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Docetaxel (75 mg/m2, intravenously on day 1 of every 21-day cycle)
Study: 24638003
Drug: Imatinib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (1 year of adjuvant therapy)
Study: 22431864
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg plus fenofibrate 200 mg
Study: 22431864
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg plus omega-3 fatty acids 2 g
Study: 20707696
Drug: Combination peer-educator
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination peer-educator and manager-training intervention
Study: 16277693
Drug: Pyridoxine supplementation
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine supplementation (50 mg daily for 30 days)
Study: 12126938
Drug: Pirfenidone (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone (800 mg, t.i.d.)
Study: 7784126
Drug: SPf66 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf66 vaccine adjuvanted with alum
Study: 1316066
Drug: Lomefloxacin 400
Normalized name: lomefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 400 mg oral dose
Study: 1316066
Drug: Lomefloxacin up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin up to 800 mg and multiple doses up to 600 mg twice daily (1,200 mg/day)
Study: 1316066
Drug: Lomefloxacin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin (all dosage regimens)
Study: 29396020
Drug: Low-intensity shockwave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity shockwave therapy sessions once per week for 6 weeks (group A)
Study: 29396020
Drug: Low-intensity shockwave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity shockwave therapy sessions twice per week for 6 weeks (group B)
Study: 29396020
Drug: Repeat treatment
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat treatment after 6 months (group A received 2 sessions per week, group B received 1 session per week)
Study: 10446869
Drug: Minocycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (100 mg twice daily)
Study: 23980091
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg per day for 2 years
Study: 18339031
Drug: Salbutamol (PC(20)
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol (PC(20) = 10.79 mg/L, PC(35) = 8.55 mg/L)
Study: 18339031
Drug: Normal controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal controls (PC(20) = 237.68 mg/L, PC(35) = 88.72 mg/L)
Study: 12674152
Drug: Antibiotic misuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic misuse in the community
Study: 12674152
Drug: Factors affecting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors affecting patient compliance to therapy
Study: 9386685
Drug: Preoperative intraaortic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative intraaortic balloon pump (IABP) treatment
Study: 7957346
Drug: Dexamethasone intervention
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone intervention (10 mg in 24 h)
Study: 7957346
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 20 mCi (740 MBq) of technetium‐99m methylene diphosphonate (99mTc‐MDP)
Study: 3591298
Drug: F1 (1.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: F1 (1.9 g of protein and 72 kcal per 100 ml)
Study: 3591298
Drug: F2 (2.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: F2 (2.7 g of protein and 69 kcal per 100 ml)
Study: 3591298
Drug: HM (0.96
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM (0.96 g of protein and 65 kcal per 100 ml)
Study: 29687303
Drug: Guava leaf
Normalized name: guava leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guava leaf extract (1 g daily)
Study: 20048227
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy guided self-help (CBTgsh)
Study: 20048227
Drug: Behavioral weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral weight loss treatment (BWL)
Study: 16156881
Drug: Ritonavir 100
Normalized name: ritonavir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 100 mg twice-daily added to nelfinavir 1250 mg twice-daily regimen
Study: 16156881
Drug: Nelfinavir 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir 1250 mg twice-daily regimen without ritonavir
Study: 8017414
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin through PVC administration set
Study: 8017414
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin through polyethylene administration set
Study: 31169407
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) with Propofol
Study: 28771503
Drug: Narrowband UVB
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Narrowband UVB treatment
Study: 26084281
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance exercise program, performed twice a week for 15 weeks
Study: 21804375
Drug: Esomeprazole/amoxicillin/levofloxacin (EAL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole/amoxicillin/levofloxacin (EAL) - 40 mg esomeprazole twice daily, 1 g amoxicillin twice daily and 500 mg levofloxacin once daily for 7 days
Study: 21804375
Drug: Esomeprazole/amoxicillin/metronidazole (EAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole/amoxicillin/metronidazole (EAM) - 40 mg esomeprazole twice daily, 1 g amoxicillin twice daily and 250 mg metronidazole 4 times daily for 14 days
Study: 17042884
Drug: Quetiapine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine monotherapy (up to 800 mg/day)
Study: 17042884
Drug: Quetiapine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine + Lithium/Divalproex (up to 800 mg/day)
Study: 17042884
Drug: Haloperidol monotherapy
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol monotherapy
Study: 8985623
Drug: Ephedrine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (50 mg)
Study: 10209349
Drug: Sumatriptan nasal
Normalized name: SUMAtriptan nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan nasal spray 5 mg
Study: 10227648
Drug: Sumatriptan nasal
Normalized name: SUMAtriptan nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan nasal spray
Study: 7696164
Drug: AVP induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVP induction chemotherapy (adriamycin, etoposide, cisplatin given every four weeks for four cycles)
Study: 7696164
Drug: EVA induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVA induction chemotherapy (cyclophosphamide, etoposide, adriamycin given every four weeks for four cycles)
Study: 7696164
Drug: MOC/AVP induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOC/AVP induction chemotherapy (methotrexate, vincristine, cyclophosphamide alternating with adriamycin, etoposide, cisplatin for two cycles)
Study: 7696164
Drug: Combined-modality maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality maintenance therapy (radiation therapy to the chest followed by MOC/EVA chemotherapy)
Study: 7696164
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy alone (without consolidating chest irradiation)
Study: 2622586
Drug: Carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnitine (2 g infusion with phleboclysis)
Study: 2622586
Drug: Tocolytics per
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocolytics per os (oral)
Study: 981
Drug: 11.2% mafenide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.2% mafenide acetate cream
Study: 981
Drug: 5% mafenide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% mafenide acetate cream
Study: 981
Drug: Carrier cream
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrier cream without glycerol
Study: 25867274
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) after breast conservation therapy (BCT)
Study: 23786655
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine (NE) 5 to 15 μg/min
Study: 19287305
Drug: multiple hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple hepatic arterial injections of Ad‐p53 (1x10 viral particles) and 5‐FU (500‐750 mg), after TACE
Study: 17885005
Drug: Soymilk (28.51
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soymilk (28.51 mg isoflavone aglycone equivalents/portion)
Study: 17885005
Drug: Soy germ
Normalized name: soy germ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy germ (37.99 mg isoflavone aglycone equivalents/portion)
Study: 8034812
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (16 sessions)
Study: 2564458
Drug: Long-term interferon
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term interferon therapy
Study: 2564458
Drug: Resumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resumption of interferon therapy
Study: 28571727
Drug: Mentha pulegium
Normalized name: MENTHA PULEGIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentha pulegium extract (330mg three times daily for 2 months)
Study: 22303583
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg kg‐1 nettle extract, three portions a day for 8 weeks
Study: 16409198
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (latex immunotherapy)
Study: 12654431
Drug: Conventional RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional RT and adjuvant chemotherapy
Study: 12654431
Drug: Conventional RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional RT plus concurrent chemotherapy
Study: 12654431
Drug: Conventional RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional RT plus concurrent chemotherapy and adjuvant chemotherapy
Study: 11140556
Drug: Adjunctive systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive systemic doxycycline (200 mg the 1st day, then 100 mg per day for 21 days)
Study: 1441695
Drug: Pimobendan 5
Normalized name: pimobendan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan 5 mg bid
Study: 3548207
Drug: Piroxicam 40
Normalized name: piroxicam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 40 mg/day for two days followed by 20 mg/day
Study: 3548207
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid 500 mg t.i.d.
Study: 3548207
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg b.i.d.
Study: 30486723
Drug: Radial Extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) - 3,000 pulses each; pressure: 1.8‐2.0 bar; frequency: 10 Hz, once a week for 8 weeks.
Study: 30486723
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of an α‐blocker and an anti‐inflammatory agent, treated for 8 weeks.
Study: 24762108
Drug: TAK-448 (0.01-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-448 (0.01-6 mg/d; single-bolus or 2-hour infusion)
Study: 24762108
Drug: TAK-448 (0.01-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-448 (0.01-1 mg/d; 14-day sc administration)
Study: 24762108
Drug: TAK-448 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-448 (12 or 24 mg sc-depot injections)
Study: 24762108
Drug: TAK-448 (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-448 (24 mg sc-depot injections)
Study: 1404679
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg aspirin twice daily
Study: 17208597
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg aspirin twice daily
Study: 8869876
Drug: Oestrogen replacement
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen replacement therapy
Study: 8582195
Drug: Combined or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined or opposed hormone replacement therapy (HRT)
Study: 28346568
Drug: 3-monthly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-monthly oral doses of 3 mg calcifediol plus daily exercise
Study: 21823415
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Back‐shu point needling and trunk exercise
Study: 19243724
Drug: Manual lymph
Normalized name: Bos taurus lymph preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual lymph drainage therapy (MLDT)
Study: 10515308
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg d-amphetamine (low-dose group)
Study: 10515308
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg d-amphetamine (high-dose group)
Study: 7733124
Drug: Cyclical etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical etidronate (400 mg/d for the first month; thereafter, 400 mg/d for 2 weeks of every 3-month period), elemental calcium (1 g/d), and ergocalciferol (0.5 mg/wk)
Study: 7733124
Drug: Calcium supplements
Normalized name: CALCIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplements only (1 g/d)
Study: 9481597
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg sibutramine
Study: 1914367
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sibutramine
Study: 7017991
Drug: 750 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg/day of chenodeoxycholic acid (CDCA) for 4 months, followed by an additional 4 months for those showing a 25% or more decrease in stone size.
Study: 31912632
Drug: Alirocumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (150 mg, subcutaneous, biweekly for 6 weeks)
Study: 28382813
Drug: Aquatic physical
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic physical training (APT) program, held twice a week for 16 weeks
Study: 25500940
Drug: Anaesthetist-directed fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthetist-directed fluid therapy
Study: 11921054
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a (30 microg weekly intramuscular injections)
Study: 2644335
Drug: Fluoxetine (ProzacR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (ProzacR, Lilly) for 8 weeks
Study: 23533318
Drug: Isoniazid (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (36 months daily)
Study: 21831926
Drug: Stay active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stay active care, muscle stretching and manual therapy (group 3)
Study: 21831926
Drug: Stay active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stay active care, muscle stretching, manual therapy and steroid injections (group 4)
Study: 18298230
Drug: Integrated cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cognitive‐behavioral therapy
Study: 18298230
Drug: 12‐step facilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12‐step facilitation therapy
Study: 17038946
Drug: Polyester collagen-coated
Normalized name: polyester-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyester collagen-coated vascular patch
Study: 10368454
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of rickets
Study: 10368454
Drug: Echocardiographic studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Echocardiographic studies before treatment
Study: 10368454
Drug: Echocardiographic studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Echocardiographic studies after treatment
Study: 8763050
Drug: Minaprine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minaprine (200 mg/d)
Study: 26922669
Drug: Synthetic cartilage
Normalized name: SHARK CARTILAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic cartilage implant
Study: 24035770
Drug: 5-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-day regimen of antibiotics after catheter exchange
Study: 24035770
Drug: 10-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-day regimen of antibiotics with catheter retention
Study: 21118681
Drug: Acarbose after
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose after 7 months of therapy
Study: 20344882
Drug: Radio Electric
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radio Electric Asymmetric Treatment (REAC)
Study: 15628696
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg sKET
Study: 15628696
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sKET
Study: 11270028
Drug: Hydroxyzine 1
Normalized name: hydroxyzine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 1 mg kg‐1
Study: 8348281
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 5 mg
Study: 8348281
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) doses ranging from 5 to 20 mg
Study: 12014167
Drug: Placebo agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo agent
Study: 23162576
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera gel (A.V. 2% oral gel)